Myocardial Infarction Activates Autoreactive CD4+ T Cells In Vivo
(A) TCR-M cells were injected into sham or MI mice on day 2 or day 7 post-surgery. CFSE dilution and CD44 expression of donor TCR-M cells is shown.
(B) Proliferation of donor TCR-M cells in lymphoid organs from the experiment described in (A).
(C) Percentage of Foxp3/CD25 expression on undivided and divided donor TCR-M cells isolated from mLN in sham and MI mice at day 2 post-surgery.
(D) CFSE dilution and CD44 expression of naive TCR-M cells in ex vivo co-culture with bulk mediastinal LN, spleen, and mesenteric LN cells isolated from sham and MI mice on day 2 and day 7 post-surgery.
(E) Heart cDC2 and migratory cDC2 percentages in mLN of sham and MI Irf4fl/fl and Irf4fl/fl.Cd11cCre mice at day 7 post-surgery.
(F) Irf4fl/fl, Irf4fl/fl.Cd11cCre, Irf8fl/fl and Irf8fl/fl.Cd11cCre mice were injected with TCR-M cells at day 2 post MI. CFSE dilution and CD44 expression of donor TCR-M cells is shown.
(G) Proliferation and CD44 expression of donor TCR-M cells in LNs and spleen from Irf4fl/fl and Irf4fl/fl.Cd11cCre mice from the experiment described in (F).
(H) Heart cDC percentages of sham and MI Irf8fl/fl and Irf8fl/fl.Cd11cCre mice at day 7 post-surgery.
(I) Proliferation and CD44 expression of donor TCR-M cells in LNs and spleen from Irf8fl/fl and Irf8fl/fl.Cd11cCre mice from the experiment described in (F). All bar graphs in Figure 7 show data as mean ± SEM (∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001), and all data are representative of two independent experiments.